While manufacturing generic drugs, the drug companies use the same active ingredients and, they have the same risks and benefits as their brand name likeness. Also, generic drugs have the same quality, strength, purity and stability as brand name drugs. The generic drugs are less expensive as compared to branded drugs as generic manufacturers do not have the investment costs of the developer of a new drug. New drugs are generally developed under patent protection. Bioequivalence is based on rate and extent, but rate and extent is depending on the absorption. Absorption is depending on drug dissolution, permeability and solubility. Firstly permeability and solubility related to biopharmaceutical classification system discovered by Gordon Amidon et al. in 1995. Bio analysis carried out with help of LC/MS and use of Solid phase extraction, Liquid/Liquid extraction, Protein precipitation.
INTRODUCTION
The key reason for performing bioequivalence testing is to ensure that the quality of generic drug products. In particular, such testing is meant to establish that there are not likely to be any differences in safety and efficacy between a generic and an innovator drug product (reference product); that is, that the products are therapeutically equivalent. Thus, in essence, bioequivalence is considered a foster of therapeutic equivalence 1 . While manufacturing generic drugs, the drug companies use the same active ingredients and, they have the same risks and benefits as their brand name likeness. Also, generic drugs have the same quality, strength, purity and stability as brand name drugs. It is seen that Generic Drugs work in the same way and in the same amount of time as branded drugs. The generic drugs are less expensive as compared to branded drugs as generic manufacturers do not have the investment costs of the developer of a new drug. New drugs are generally developed under patent protection. The studies should provide an objective means of critically assessing the possibility of substituting one for the other. Two products marketed by different licensees, containing same active ingredients, must be shown to be therapeutically equivalent to one another in order to be considered interchangeable. Thus, because of the importance of generic drugs in health care, it is imperative that the pharmaceutical quality, safety and efficacy of generics should be reliably compared with the corresponding innovator drugs (brandname drugs). According to Hatch-Waxman act the expansion of the generic drug industry, before the Act only 12 % of all prescriptions in the United States were generics, and in 2007, 65 % of prescriptions dispensed in the U.S were for generic drugs (Generic Pharmaceutical Association, 2008). . The assessment of "interchangeability" between the innovator and generic products is carried out by a study of "in vivo equivalence" or "bioequivalence". The apposite situations in which bioequivalence studies are required include; · when the proposed marketed dosage form is different from that used in pivotal clinical trials; · when significant changes are made in the manufacture of the marketed formulation; · When a new generic product is tested against the innovator's marketed product. Based on this background, bioavailability (BA) and bioequivalence (BE) information has been determined to have practical and public health value for pharmaceutical industries, regulatory agencies, patients and practitioners. To understand the basis of the argument around innovator drug and generic exchangeability a thorough understanding of the terms associated with generic drugs is needed.
Bioavailability
"Bioavailability means the rate and the extent to which the active drug ingredient of therapeutic moiety is absorbed from a drug product and becomes available at the site of action" (FDA Official Statement in 1977), "The rate at which, and the extent to which the drug substance and/or its active metabolites reaches the systemic circulation." (International Consensus Statement in 1991)
Bioequivalence
A relative term which denotes that the drug substance in two or more dosage forms, reaches the systemic circulation at the same relative rate and to the same relative extent i.e., their plasma concentration time profiles will be identical without significant statistical difference. Bioequivalence is based on rate and extent, but rate and extent is depending on the absorption. Absorption is depending on drug dissolution, permeability and solubility. Firstly permeability and solubility related to biopharmaceutical classification system discovered by Gordon Amidon et al. in 1995. The BCS used in vitro dissolution to establish bioequivalence for highly soluble and highly permeable compounds 3 . . The BCS became a tool in the regulation of bioequivalence of oral drug products. Due to substantial credit of the BA/BE concept all over the world, tremendous advancements have been made by the FDA as well as various national, international and supranational regulatory authorities. In parallel, pharmaceutical industry and academia are also contributing exclusively in the area of assessment of BE 5 . Currently available advances to determine BE of generic products are largely standardized due to discussion and consensus reached among various stakeholders at numerous national and meetings, conferences, and workshops (e.g. American Association of Pharmaceutical Scientists, Federation International Pharmaceutique). Thus the currently available scientific and regulatory guidance documents are due to the combined efforts of industry, academia and regulatory scientists. Every country now has its own individual regulatory authority as well as regulatory guidance for BA/BE studies and the magnitude of judgment of BE of drug product is influenced by the regulatory environment of the respective country of marketing. The regulatory authorities of some of the countries are listed below Table 6, 7 . Thus there is a greater need to harmonize the regulatory environment globally for BE assessment as far as practicable so that the drug product marketed in different parts and regions of the world would have optimum drug product quality in terms of fungibility.
Methods of Assessments
The assessment of BE of different drug products is based on the central assumption that two products are equivalent when the rate and extent of absorption of the test/generic drug does not show a significant difference from the rate and extent of absorption of the reference/brand drug under similar experimental conditions as defined. As per the different regulatory authorities, BE studies are generally classified as [8] [9] [10] [11] . · Pharmacokinetic endpoint studies. · Pharmacodynamic endpoint studies. · Clinical endpoint studies. · In vitro endpoint studies. Clinical Phase (Bioequivalence) study includes · Pre-study · During study · Post study.
In the pre-study before trial starting the test are performed by phlebotomist and those subject normally fit that includes in trial otherwise they are omitted and in during study (Fed or Fast) after dosing the blood collected and centrifuged at 3500 RPM stored at -70
• C temperature. The sample collected as Analytical sample and Control sample with proper labeling. Analytical sample are analyzed with help of LC/MS. Control sample stored at ± 3 years. In post study the subject vital sign and other test are performed [12] [13] [14] [15] . 
Solid phase extraction
In solid phase extraction the analyte is deposited on stationary phase then pass buffer solution, absorption takes place and analyte dissolve these shows percentage concentrate in LC/MS.
Liquid/Liquid extraction
In Liquid/Liquid extraction all the liquid extraction is evaporated and only the analyte remain the pass mobile phase which shows concentration in LC/MS.
Protein precipitation
In Protein precipitation the plasma and buffer ammonium for mate added then precipitate protein and cooling in centrifuge for 30 minutes; then lastly decanted only upper layer spiked/aliquot which shows in LC/MS [17] [18] [19] [20] . On the above information determine the exact concentration of the unknown drug matching with known drug [21] [22] [23] [24] .
Labeling

Biopharmaceutical Classification System
During the last two and half decade, bio pharmaceutics has been undergoing a revolution from drug discovery to drug regulatory standards and harmonization. Bio pharmaceutics is based on the chemical and physical properties of drug content and the formulation, physiology of the route of administration. Nowadays, many particles are classified through screening processes and promising candidates enter into drug pipelines for further in vitro and in vivo tests. At the end of the development process stands the approval by the regulatory agencies 25-28. The BCS system helps for drug solubility and permeability, that drug with high solubility and high permeability which cross rapidly plasma membrane and shows quick action [29] [30] [31] [32] [33] [34] .
CONCLUSION
In bioequivalence study the use of test drug correlating with reference drug and in this study use of ingredient are same as that of the reference drug. Thus the bioequivalence study drug stability, safety, strength are same compare to brand drug. Here general discussion of bioequivalence study.
